|
|
|
By Allison Proffitt
June 14, 2010 | The Victoria Life Sciences Computation Initiative (VLSCI) in Victoria, Australia, has announced that it will have the world’s largest life sciences-dedicated supercomputer by 2012. The purchased IBM Blue Gene machine is expected to have around 64,000 cores, says Justin Zobel, professor of computer science and software engineering at the University of Melbourne, and head of the supercomputer project.
Zobel believes that a supercomputer of this power is essential to advancing life science research. “A machine of that size enables you to envision things you would not otherwise consider,” says Zobel. “It’s the exact opposite of [cloud computing]. The cloud is a very standardized computing resource available in a very flexible way at any scale depending on what you’re prepared to pay for…. But it doesn’t provide supercomputing. A bunch of computers in the same place is not the same as supercomputing.”
Zobel mentions “modeling organs based on a detailed simulation of the individual cells of the organ—such as the heart or brain,” as a potential project for the supercomputer, but the specifics are up to the researchers using the machine. “We want to see projects of that scale—things that are genuinely revolutionary—become enabled here in Victoria,” he says.
Victoria has more than 10,000 life sciences researchers based in the state capital at the University of Melbourne and at several other research institutes in the area. The Victorian government wanted to underpin some of the life sciences research going on in the state with a strong commitment to computing. In addition to partially funding the purchase of the supercomputer itself, the government set up the Victoria Life Sciences Computation Initiative.
|“What the VLSCI includes is a decent sized team of people, some of whom are IBM employees, some of whom are VLSCI employees, whose job it is to help life scientists make the best use of the machine,” explains Zobel.
The supercomputer itself will be housed in the Peak Computing Facility, the heart of the VLSCI. The PCF currently houses an SGI Altix with 3 racks, 1088 cores, and 10 teraflops that is in use. An IBM iDataPlex machine of 78 nodes capable of 6.6 teraflops has been delivered. The Blue Gene will come in two phases: a Blue Gene/P 8192-core machine capable of 27 teraflops will arrive in a few weeks. The 2012 machine should be about 20 times that capacity. Once that supercomputer is delivered, the Blue Gene/P will be returned to IBM, but the iDataPlex and Altix machines will stay.
The VLSCI was announced two years ago, and the Initiative is staffed jointly by University of Melbourne researchers and IBM researchers. The university and IBM opened a collaborative laboratory in mid-February, which Zobel calls an outpost of IBM’s Watson Research Center.
Compute power on the supercomputer will be open to all Victoria-based researchers and subject to a grant process in which projects are granted compute time and support time based on scientific merit. The grant process is open now, and Zobel hopes to be creating user accounts on the Blue Gene/P by early August.
Turning Genomics Data into Practical Insight With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can: - Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines.
- Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image).
Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands.
New Complimentary Market Survey… Collaborations and Communications Within Drug Discovery Research This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns. An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
Scientific Software Engineer
Boston MA
$70,000 to $95,000
Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET.
Apply at http://jobs.tessella.com
Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes. As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers. This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions. It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply
Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules. It is therefore suitable for use in a variety of markets including scientific research and clinical applications. As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team. The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market. This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company. Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial leadership, who wish to apply a fresh approach to existing markets. Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries. We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products. Click to Apply
|
|
|